Vitrolife AB (VTRLY) Kazanmak

Vitrolife AB develops, produces, and markets products for creating, prolonging, and improving life. The company is headquartered in Goeteborg, Vastra Gotalands and currently employs 1,151 full-time employees. The company went IPO on 2001-06-26. The Company’s product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. The company also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The firm is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.